ADRA2A recombinant proteins and antibodies

Alpha-2A Adrenergic Receptor (ADRA2A), also known as ADRA2R or ADRAR, is a member of the alpha-adrenergic receptor family, predominantly found in the central nervous system, cardiovascular system, and various immune cells. As a G protein-coupled receptor (GPCR), ADRA2A regulates multiple physiological processes by modulating neurotransmitter release. Its primary function is to inhibit the release of norepinephrine through a negative feedback mechanism, thereby regulating blood pressure, heart rate, anxiety, pain perception, and neurotransmitter balance. ADRA2A’s critical role in the nervous system makes it a promising target for the treatment of neurological disorders, cardiovascular diseases, and addiction.

Clinically, ADRA2A agonists, such as clonidine, have been used to treat hypertension and certain neurological conditions like anxiety and pain management. Clonidine works by activating ADRA2A receptors, which inhibit norepinephrine release, lowering blood pressure and alleviating anxiety. However, side effects such as drowsiness and hypotension have limited the broader use of ADRA2A agonists. Therefore, researchers are focused on developing more selective and precise ADRA2A agonists and antagonists with fewer side effects.

ADRA2A antagonists also hold potential in treating addiction-related disorders, especially alcohol and drug dependence. By antagonizing ADRA2A receptors, these drugs can reduce withdrawal symptoms and inhibit addictive behaviors, enhancing treatment outcomes. In recent years, more companies have begun to explore drug development targeting ADRA2A, especially in treating neurological and cardiovascular diseases. Leading pharmaceutical companies are actively working on innovative therapies that target ADRA2A. For example, companies like Apexigen are researching ADRA2A agonists and antagonists for the treatment of anxiety, depression, and neuropathic pain. In addition, major companies such as Johnson & Johnson and Pfizer are conducting clinical studies to evaluate the efficacy of ADRA2A-targeted drugs in treating cardiovascular diseases, psychiatric disorders, and addiction. As research into ADRA2A mechanisms advances, it is expected that more innovative drugs targeting this receptor will enter clinical trials, offering new therapeutic options for various diseases.

To assist in the development of ADRA2A-targeted drugs, DIMA BIOTECH can now provide full-length ADRA2A recombinant membrane protein developed by its nanodisc membrane protein platform. ADRA2A nanodisc is an optimal solution for screening small molecules targeting ADRA2A with its natural structure. Furthermore, DIMA BIOTECH has also prepared a ADRA2A single B cell seed library, from which lead antibody molecules can be obtained in as fast as 28 days.